concern
rais libr estim see path product
abbott pois acceler
remain construct multipl driver
concern price churn despit upcom
innov potenti expans
libr appeal broad rais us sale estim
respond believ libr extrem use popul
note similar level util intens popul
non-intens popul given price point libr potenti
success penetr broader popul expect
abbott make push channel follow privat pay reimburs
given blood glucos monitor bgm franchis rais us libr
estim survey share result well earli
track data show patient add sinc decemb launch given
recent momentum estim could prove conserv see path
bull case revenu bp corpor growth
privat pay reimburs come earlier year longer term libr reach
patient across popul drive us
revenu enthusiasm libr key driver recent abbott
upgrad see
rise tide lift boat market penetr
expect penetr increas anoth next two year
line expect survey current dexcom share
us expect slip survey suggest libr
captur share us market next two year line
earli dilig led downgrad equal-weight see
downgrad survey suggest patient like
switch competit devic within month abbott libr
guardian launch level competit churn prove accur would
account underli us guidanc call upper singl
digit growth said survey account earlier time
repres broader market continu glucos monitor
insight insid full share detail said outlook libr
greater threat nave continu glucos monitor cgm user less
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
intens manag popul guardian threat dexcom
core especi current anima pumper survey expect
attrit skew toward libr vs guardian like
driven price form factor factori calibr design
price dynam shift incumb fare
respond note insur coverag pocket cost greatest
driver brand choic note pocket cost critic
limit adopt see exhibit launch libr guardian
medicar reimburs shift market dynam recent discuss
indic price deflat assum price declin
guidanc y/i growth innov
expans key posit price remain underappreci risk
becom especi import hardwar revenu total
medicar market smaller investor think medicar repres
patient us popul given inertia adopt patient
mortal could see smaller address market opportun
discuss insight day survey suggest medicar
popul like use follow reimburs may
smaller investor expect like onboard medicar
patient addit backlog togeth would
repres risk adjust medicar market impli survey
still believ medicar key us growth deliv
revenu despit earlier expect libr coverag said
follow year meaning upsid may limit libr guardian coverag
lower reimburs slower adopt curv smaller market
pois near-term acceler diabet survey suggest
patient wait upgrad guardian
switch competit pump result impli backlog
remain intact despit delay broader distribut resolv
suppli constraint could materi catalyst confid increas
rapid acceler sustain ldd growth diabet
medtron ad bp corpor growth
construct driver despit survey estim
pediatr pump popul pediatr multipl daili
insulin inject mdi popul like switch avail
focu market less concern
survey result believ lean toward user ii
tubeless dispos offer uniqu continu remain attract
market iii us market freez seen
reemerg three quarter see us growth actual
acceler period also see multipl driver upsid
year includ medicar anima dash go direct ex us long-term
horizon ap sustain dd us patient growth
continu see path ww revenu
morgan stanley alphawis survey methodolog on-line interview
conduct high volum us endocrinologist alphawis
cgm adopt acceler market remain penetr survey suggest
cgm penetr us popul increas y/i
expect increas anoth two year penetr
intens insulin popul increas y/i expect increas
two year survey skew toward peer lead physician earli adopt
like overestim current market penetr base dilig estim us
penetr high teen expect futur market penetr
line survey expect addit penetr next two
exhibit cgm us market penetr estim alphawis survey respond
year
market share dynam flux libr appear clear winner survey
suggest split medtronic/dexcom us cgm market
suggest survey bia popul closer
share respond believ libr captur share market next
two year line earli dilig led downgrad
equal-weight see downgrad estim libr reach patient
across popul drive us revenu
rise tide lift boat survey suggest patient
like switch competit devic libr guardian within month believ
guidanc growth ww patient base driven mid-teen
growth us compris msd-hsd growth core us augment medicar
patient impli us patient growth level seen
like emb headwind increas competit price
pressur level competit churn report survey prove accur
would account underli us guidanc said
survey account earlier time repres broader
survey expect attrit skew toward libr guardian
patient like switch anoth devic survey expect
switch libr believ driven libr attract
price point low profil form factor factori calibr design partial off-set
lack alarms/alert result reinforc view diabet commun
begin see equit devic accuraci improv
accept level mard across devic note survey accur
test impact devic given lack clariti function
launch time time survey
exhibit cgm us market share breakdown estim alphawis survey respond
year
exhibit percent patient like switch libr guardian first month
exhibit respond believ attrit would skew slightli toward libr guardian
libr util span broader patient popul respond believ libr
extrem use popul addit believ libr
very/extrem use intens popul believ
very/extrem use non intens popul abbott bgm
franchis face multi-year price headwind believ libr current price
point becom competit offer patient reli
primarili finger stick glucos monitor
physician concern remain address time survey highlight three
key factor may limit libr adopt note lack alarm note
inaccuraci extrem note lack data reason
recommend libr today believ manag work address alarm
accuraci concern devic data concern fade year
begin attd februari found myriad libr posters/discuss
see attd scientif program includ trial libr vs
argument superior devic believ abstract support belief
libr capabl adequ help deliv better diseas control across
patient popul note unfamiliar libr expect chang
year driven abbot dtc campaign libr coverag see
exhibit libr util broad across patient
 use
exhibit reason physician would recommend libr
lack alarm
inaccuraci extrem
familiar libr
medicar tam may smaller expect medicar repres patient
us popul given inertia adopt patient mortal see
insight day see smaller address market opportun survey suggest
medicar popul like use follow reimburs
line thought intens medicar popul patient
survey suggest intens patient would use adopt
like slower market less near term catalyst like
onboard medicar patient addit backlog
repres risk-adjust medicar opportun perhap larger
piec earli adopt still believ medicar key us growth
deliv revenu despit earlier expect libr coverag
given amort payment said follow year meaning upsid may
limit libr guardian coverag lower reimburs smaller
percentag like user
exhibit medicar patient like use follow reimburs
driver cgm adopt brand choic respond note
insur coverag pocket cost greatest driver brand choic
note pocket cost critic limit adopt
result surpris cost long cite rate limit adopt
launch libr guardian shift market dynam recent
brand choic limit offer enlit platform
seen unreli inaccur devic broader choic consum
improv function accuraci across devic expect cost
greater focal point consum payer compani near term
cgm price pressur come commentari
earlier month suggest sensor price like declin
would partial diminish libr price advantag price declin possibl
 guardian alreadi bake guidanc y/i
growth believ guidanc emb competit price
headwind
exhibit driver decis make brand choic
insur coverag pocket
number daili calibr requir
exhibit import drawback limit adopt important/crit
pocket expens
size sensor form factor
difficulti interpret manag inform
requir finger stick calibr
limit awar
lower cost drive greater libr adopt survey suggest patient
like switch libr price pariti nearli like switch
sensor price discount peer convers may seem aggress
libr rapid adopt ex us region reimburs libr
surpass run rate support view libr grown
patient base ex us vs driven cost therapi less half
cash pay patient said us wide reimburs
libr sensor cost vs unclear meaning cost
differenti consum up-front hardwar cost lower vs
appeal new patient total cost therapi
cheaper assum deduct co-pay/co-insur continu
believ libr like compet nave cgm user core base
expect modest churn base libr expect off-set
approv
exhibit patient likelihood switch libr base price
price pariti cgm
price discount compar
option
libr medicar reimburs earlier month announc
coverag libr thought libr medicar approv possibl
like month ahead street expect abbott distribut patient
dme channel similar medicar
code libr retail pharmaci channel sensor
 receiv vs averag sensor receiv
howev monthli sensor reimburs dme
product import structur take-away payer like look
flatter landscap like price like valu long-term question medicar
think dispar pleas see januari note addit thought
penetr continu survey show sign slow mdi convers
survey suggest us pump penetr increas today two
year ago expect add next two year penetr
intens insulin popul increas today year ago
expect add pt next two year similar data seen cgm
respons think survey overestim current market penetr
estim closer us popul
share shift expect mute includ shutter anima
respond see minim share shift next two year rel
unchang expect tandem gain share
anima give pt share survey share split gener line
current assumpt surpris minim share gain medtron
light launch tandem share gain make sens us enthusiasm
integr slim pump sensor high addit
pgl slim expect hybrid close loop pump late
note survey run broad understand shutter
us canada anima busi expect gain
like underappreci turn world upsid assum
would drive bp pt growth
respect comment recent investor confer anima patient
tailwind refrain comment materi could continu
think guidanc conserv around point manag see medicar
exhibit us market penetr estim report alphawis survey respond
year
exhibit us market share breakdown estim alphawis survey respond
year
remain critic limit pump adopt long cite
critic limit cgm pump adopt survey show
respond believ pocket cost critic limit adopt
expect see consum cost declin medium term innov
closed-loop pump ap support current price well competitor exit
market eas use pump reliability/accuraci difficulti interpreting/manag data
limit factor believ next-gen devic
tandem integr slim dash/horizon ap meaning improv
metric
pocket expens
eas use
difficulti interpret manag inform
demand remain sticki despit delay patient wait
upgrad guardian switch competit pump
suppli constraint given limit manufactur capac caus
lag time broader distribut result encourag
backlog remain intact compani finish process
prioriti access patient expect broader distribut spring confid
increas sustain ldd growth diabet ad
bp corpor growth
exhibit patient expect switch competit pump due guardian
exhibit percent patient believ delay upgrad pump/cgm wait
encroach pediatr mdi popul concern
greatest appeal adult pump popul survey expect
switch devic surpris given target popul
survey expect convers pediatr pump popul convers
pediatr mdi popul focu pediatr mdi popul
less concern survey result tubeless dispos
offer uniqu continu remain attract certain nich market
addit us market freez seen reemerg three
quarter see remain confid medicar coverag anima
dash/horizon ap sustain dd us patient growth
exhibit estim convers vari age insulin deliveri popul
price target base multipl base case
ep peer line histor premium
see multipl reflect abbott better peer top bottom line growth
nutrit recov china imf headwind fade aler stabil gradual return
market growth new product libr confirm mri heartmat
launch acceler organ growth management execut deal synergi
valu driver includ continu oper margin expans core abbott
combin cost synergi execut st jude aler organ growth
acceler driven devic product launch diabet ep heart failur
risk price target includ emerg market macro slowdown fx headwind
strengthen us dollar failur deliv synergi target and/or growth
acceler st jude aler
price target base ev/sal multipl line smid
cap devic compani support dcf valuat assum wacc
risk price target includ guardian libr competit greater
expect limit new patient start materi increas attrit ii dexcom
traction medicar limit coverag guardian libr come sooner
expect iii libr forc signific price pressur limit path profit
iv delay failur pipelin catalyst
price target reflect ev sale multipl base case
line high growth smid cap peer ev sale ex us growth
improv meaning ypsome gross up near term disrupt
manag us growth remain stabl driven anima convers
mdi pediatr posit insul omnipod risk remain
downsid risk price target includ insulet lose market share ii
limit convers anima patient iii ypsome disrupt greater
expect iv dash horizon ap timelin slip path profit becom
less clear updsid risk includ minim disrupt ypsome transit ii
disclosur addit drug deliveri deal ii greater abil drive
